Antikor takes aim at solid tumours with antibody-fragment conjugates

See Scrip Analysis 8th December 2017

Emerging Company Profile: The UK's Antikor Biopharma is advancing antibody fragment-drug conjugates (FDCs) closer to the clinic with plans for its first human study in 2019 or 2020.

https://scrip.pharmaintelligence.informa.com/SC099910/Antikor-Takes-Aim-At-Solid-Tumors-With-AntibodyFragment-Conjugates